By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1971 Old Cuthbert Road

Cherry Hill  New Jersey  08034  U.S.A.
Phone: 856-433-6088 Fax: 856-354-1077



Company News
Nuvilex (NVLX) Contracts With University Of Veterinary Medicine In Vienna To Conduct Preclinical Studies On The Use Of Cell-In-A Box® To Develop Diabetes Treatment 10/20/2014 7:30:52 AM
Nuvilex (NVLX) Secures Worldwide License For Insulin-Producing Cells From University of Technology Sydney, For Use In Developing Diabetes Treatment 10/16/2014 7:49:40 AM
Nuvilex (NVLX) Applies To FDA For Orphan Drug Designation For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 10/13/2014 8:20:43 AM
Nuvilex (NVLX) Announces Strategic Changes To Leadership Team And Appoints Prof. Dr. Walter H. Gunzburg As Chief Scientific Officer 10/1/2014 10:10:57 AM
Nuvilex (NVLX)'s Partner, Austrianova, Publishes Scientific Review Article Emphasizing Use Of Cell-In-A-Box® For Treatment Of Diabetes 9/22/2014 8:06:20 AM
Nuvilex (NVLX) Updates Shareholders On Recent Activities And Discusses Future Plans For Development Of Treatments For Cancer And Diabetes 9/18/2014 11:29:48 AM
Nuvilex (NVLX)'s Partner, Austrianova, Receives Prestigious Emerging Enterprises 2014 Best Innovation Award In Singapore 9/8/2014 7:28:11 AM
Nuvilex (NVLX) Submits Application For Orphan Drug Designation To The European Medicines Agency For Its Cell-In-A-Box® Treatment For Pancreatic Cancer 9/2/2014 10:41:03 AM
Nuvilex (NVLX) Begins Preclinical Studies With Translational Drug Development To Determine If Nuvilex's Unique Cancer Treatment Can Slow Accumulation Of Malignant Ascites Fluid 8/20/2014 7:36:40 AM
Nuvilex (NVLX) Announces Publication Of Combined Results Of The Initial Phase 1/2 Clinical Trial And A Second Phase 2 Clinical Trial Of The Cell-In-A-Box® Plus Ifosfamide Combination In Patients With Advanced, Inoperable Pancreatic Cancer 8/14/2014 7:45:24 AM